A Phase II Study of Poziotinib in EGFR Exon 20 Mutant Advanced Non-Small Cell Lung Cancer (NSCLC)

Trial Profile

A Phase II Study of Poziotinib in EGFR Exon 20 Mutant Advanced Non-Small Cell Lung Cancer (NSCLC)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Sep 2017

At a glance

  • Drugs Poziotinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 28 Sep 2017 According to a Spectrum Pharmaceuticals media release, data from the study will be presented an oral presentation at the 18th International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer.
    • 20 Jul 2017 Planned number of patients changed from 30 to 60.
    • 02 May 2017 According to a Spectrum Pharmaceuticals media release, Interim results are expected before end of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top